A statement from the drug maker said it is a first-cycle NDA (new drug application) approval for the Proprietary Products Group, a substantial milestone within the pharmaceutical industry. Impoyz (clobetasol propionate) cream, 0.025 per cent, is a high-potency topical steroid approved for the treatment of ...
Read more: DRL's subsidiary receives FDA nod for anti-psoriasis cream